303 related articles for article (PubMed ID: 27913529)
1. Ph-like acute lymphoblastic leukemia.
Tran TH; Loh ML
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):561-566. PubMed ID: 27913529
[TBL] [Abstract][Full Text] [Related]
2. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
3. Why and how to treat Ph-like ALL?
Roberts KG
Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
[TBL] [Abstract][Full Text] [Related]
4. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.
Khan M; Siddiqi R; Tran TH
Semin Hematol; 2018 Oct; 55(4):235-241. PubMed ID: 30502852
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
6. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.
Harvey RC; Tasian SK
Blood Adv; 2020 Jan; 4(1):218-228. PubMed ID: 31935290
[TBL] [Abstract][Full Text] [Related]
7. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
Pui CH; Roberts KG; Yang JJ; Mullighan CG
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
[TBL] [Abstract][Full Text] [Related]
8. Can Ph-like ALL be effectively targeted?
Maese L; Raetz EA
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101096. PubMed ID: 31779971
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
[TBL] [Abstract][Full Text] [Related]
11. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
12. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
13. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.
Jing Y; Chen H; Liu M; Zhou M; Guo Y; Gao C; Wang Q; Li H; Zhao Y; Bo J; Huang W; Zhu H; Zhang Y; Yu L
PLoS One; 2014; 9(11):e110431. PubMed ID: 25415187
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children].
Guo Y; Liu TF; Ruan M; Yang WY; Chen XJ; Zhang L; Wang SC; Liu F; Zhang JY; Liu XM; Qi BQ; Zou Y; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Aug; 17(8):819-24. PubMed ID: 26287346
[TBL] [Abstract][Full Text] [Related]
16. Clinical screening for Ph-like ALL and the developing role of TKIs.
Tran TH; Tasian SK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):594-602. PubMed ID: 36485164
[TBL] [Abstract][Full Text] [Related]
17. Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia.
Chiaretti S; Gianfelici V; O'Brien SM; Mullighan CG
Am Soc Clin Oncol Educ Book; 2016; 35():e314-22. PubMed ID: 27249738
[TBL] [Abstract][Full Text] [Related]
18. Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?
Tran TH; Tasian SK
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101331. PubMed ID: 34865703
[TBL] [Abstract][Full Text] [Related]
19. T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.
Sano H; Mochizuki K; Akaihata M; Kobayashi S; Ohto H; Kikuta A
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27781393
[TBL] [Abstract][Full Text] [Related]
20. Philadelphia chromosome-like acute lymphoblastic leukemia.
Tasian SK; Loh ML; Hunger SP
Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
